In the first half of 2025, four new medicines developed by the pharmaceutical company Farmak received registration in the United Kingdom.
These include a medicine for the symptomatic treatment of stable angina for sedation in hospital settings, a radiopaque contrast agent for diagnostic imaging, and a treatment for the rapid correction of severe vitamin B and C deficiencies.
Currently, Farmak manufactures 8 products at its production site in Kyiv, which are registered in the United Kingdom and distributed under the Farmak International brand. In addition to the newly registered products, these include medicines for the treatment of cardiovascular diseases, anesthetics, contrast agents for magnetic resonance imaging (MRI), and medicines to reduce elevated intraocular pressure.
These new registrations confirm Farmak’s Group dynamic growth and strengthening presence in one of Europe’s most complex and demanding pharmaceutical markets.
It is worth noting that in September 2024, the Farmak International acquired the UK-based A&S Pharma Holdings Ltd., a company specializing in the distribution of generic medicines. This acquisition marked an important milestone in the implementation of Farmak’s corporate strategy “Farmak 2.0: from Local to Global Success.”
Today, the Farmak Group is a global pharmaceutical business founded in Ukraine in 1925, with manufacturing facilities in Ukraine and Spain, as well as international offices and subsidiaries in 11 countries worldwide. The company exports its products to more than 60 countries, including 15 EU member states, and manufactures in full compliance with GMP (Good Manufacturing Practice) standards.
Farmak International is responsible for the global operations of the Farmak Group of Companies, asset management, and expansion into international markets.
